ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006.
Hilger
R A
RA
Universitätsklinikum Essen, Innere Klinik und Poliklinik (Tumorforschung), Abteilung Pharmakologie Antineoplasticher Substanzen, Essen, Germany.
Kredke
S
S
Hedley
D
D
Moeller
J G
JG
Bauer
R J
RJ
Stellberg
W
W
Seeber
S
S
Scheulen
M E
ME
Strumberg
D
D
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D001557:Benzenesulfonates / Q000008:administration & dosage / Q000494:pharmacology*; D015415:Biomarkers; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D008875:Middle Aged; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism*; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D010766:Phosphorylation; D019908:Proto-Oncogene Proteins c-raf / Q000037:antagonists & inhibitors*; D011725:Pyridines / Q000008:administration & dosage / Q000494:pharmacology*; D000077157:Sorafenib
D001557:Benzenesulfonates; D015415:Biomarkers; D004791:Enzyme Inhibitors; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D019908:Proto-Oncogene Proteins c-raf; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases